U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07135128) titled 'A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors' on Aug. 14.
Brief Summary: This is a single-center, single-arm clinical study to evaluate the safety, tolerability and preliminary efficacy of [225Ac]Ac-FAPI-XT injection in patients with FAP-positive advanced solid tumors.
Study Start Date: Oct. 14, 2024
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumor
Intervention:
DRUG: 225Ac-FAPI-XT
Patients will receive [225Ac]Ac-FAPI-XT(XT117) administration at an interval of 6 weeks between each dose.
Recruitment Status: RECRUITING
Sponsor: Xiaorong Sun
Information provided by (R...